Autoinflammatory & rare systemic diseases
Prophylactic colchicine for familial Mediterranean fever: response rates revisited
Authors' conclusion
We found a relatively large group of FMF patients with inadequate response to colchicine.
Study context
- Population
- Consecutive familial Mediterranean fever (FMF) patients treated with colchicine
- Participants
- 106 patients
- Exposure
- M694V homozygotes vs all other MEFV genotypes combined
- Outcome
- Colchicine response: adequately controlled (0–2 attacks in past year) by MEFV genotype
- Follow-up
- Past year
Methodological detailsconsecutive patients, medical file review
- Consecutive patients
- Medical file review
Main finding
As reported in the abstract
Adequately controlled (zero to two attacks in past year)
P < 0.002
Observational data: associations, not effects.
Further findings
Poorly controlled (more than six attacks in past year)
P < 0.001
Colchicine dose, adequately controlled vs rest of cohort
- Adequately controlled patients received a lower colchicine dose than the rest of the cohort
- P = 0.042
Safety
- None of the patients had amyloidosis
- 0
Original publication
Prophylactic colchicine for familial Mediterranean fever: response rates revisited. Scand J Rheumatol. Published 5 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →